RedHill Biopharma Ltd.

RedHill Biopharma Ltd. is a specialty biopharmaceutical company dedicated to developing and commercializing therapies for gastrointestinal, infectious, and oncologic diseases. The company's mission is to deliver innovative medicines that enhance patients' lives. Headquartered in Tel Aviv-Yafo, Israel, RedHill Biopharma also maintains a significant U.S. commercial presence with offices in Raleigh, North Carolina.

RedHill Biopharma's commercial portfolio includes Talicia, an FDA-approved treatment for H. pylori infection in adults, and Aemcolo, indicated for traveler's diarrhea in adults. The company also boasts a robust pipeline of proprietary mid-to-late-stage clinical drug candidates. Key investigational therapies include opaganib, being explored for various oncology indications (such as neuroblastoma and cholangiocarcinoma), viral infections (like ARDS and Ebola), and inflammatory and metabolic diseases; RHB-107 (upamostat) for viral infections, oncology, and inflammatory gastrointestinal diseases; RHB-102 (Bekinda) for gastrointestinal issues including acute gastroenteritis and oncology support; and RHB-204 for pulmonary Mycobacterium avium complex disease and Crohn's disease.

Recent notable developments for RedHill Biopharma include the closing of a private placement of up to $19.4 million in June 2026, aimed at supporting liquidity and potential product acquisitions. In the same month, opaganib received FDA Rare Pediatric Disease Designation for neuroblastoma, adding to its existing Orphan Drug Designation. The company also initiated enforcement proceedings for an $11 million New York Supreme Court judgment against Kukbo. Dror Ben Asher serves as the Chief Executive Officer. RedHill Biopharma is primarily focused on U.S. commercialization and development, leveraging its pipeline to address significant unmet medical needs.